Five-year data shows lasting benefit for patients with advanced gastroesophageal cancers treated with nivolumab and chemotherapy.

Nivolumab plus chemotherapy improved long-term survival in Chinese patients with advanced gastric, GEJ, or esophageal cancer.

The addition of lenvatinib/pembrolizumab to TACE showed a numerical improvement in PFS, but longer follow-up is necessary to ...

Findings from an exploratory 2a study showed improvements in patients with cancer cachexia with PH284 compared with placebo.

Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...

Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...

Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...

Panelists discuss practical insights and learning opportunities through interactive examination of a patient case.

Sasanlimab plus BCG improved outcomes in high-risk, BCG-naive non-muscle-invasive bladder cancer. Sasanlimab (PF-06801591) added to BCG therapy significantly improved outcomes for patients with ...

Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...

Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...

Liso-Cel Shows Comparable Real-World Outcomes in Relapsed/Refractory LBCL ...